Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

New Vector Smart laboratories in Florida and Indiana expand Co-Diagnostics’ surveillance network and support broader PCR-based mosquito-borne disease monitoring.

Rhea-AI Summary

Co-Diagnostics (CODX) has completed two new Vector Smart® mosquito surveillance laboratory installations in Florida, with installation and customer training underway for an additional laboratory in Indiana.

The new sites activate previously announced orders and expand a Vector Smart network that has served customers in 21 U.S. states, including 7 mosquito abatement districts in Florida. Rising dengue activity in Florida this season includes 73 locally acquired cases across five counties and 14 dengue-positive mosquito pools, underscoring demand for decentralized molecular surveillance. Vector Smart delivers rapid, local PCR data for mosquito-borne disease monitoring and is designed as a scalable, multi-test platform that can be applied to multiple pathogens as surveillance priorities change.

Positive

• Two Vector Smart labs fully installed in Florida, with another installation and training underway in Indiana
• Vector Smart network now serves customers across 21 U.S. states, including 7 mosquito abatement districts in Florida
• Recent independent evaluation of the Vector Smart VZDC assay by a state public health laboratory supports broader platform adoption
• Recent first international Vector Smart deployment and ongoing third-party validation add credibility to the expansion program

Negative

• None.

Market Context

CODX was unchanged at 0% before publication, while the September 1 Vector Smart installation announc...

Analysis

CODX was unchanged at 0% before publication, while the September 1 Vector Smart installation announcement was followed by a 4.03% decline; the current deployments added operational progress without a comparable pre-publication move.

Key Figures

Florida installations: 2 laboratories Indiana installation: 1 laboratory Florida dengue cases: 73 cases +3 more

Florida installations

2 laboratories

Vector Smart installations completed

Indiana installation

1 laboratory

Installation and customer training underway

Florida dengue cases

73 cases

Locally acquired cases recorded across five counties

Dengue-positive mosquito pools

14 pools

Florida surveillance report for the week ending August 29, 2026

U.S. state network

21 states

Vector Smart network customer reach

Florida mosquito abatement districts

7 districts

Customers served within the Vector Smart network

Historical Context

1 past event · Latest: Sep 01

1 event

1. Sep 01

   Vector Smart installation

   24h Move

   -4.0%

   First international Vector Smart installation expanded platform beyond 21 U.S. states

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular diagnostics, arbovirus surveillance, pcr, assay

4 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

arbovirus surveillance medical

"Florida Department of Health's arbovirus surveillance report"

Monitoring and reporting systems that track infections caused by arboviruses—viruses spread by biting arthropods such as mosquitoes and ticks—by testing humans, animals, insect vectors, or environmental samples and compiling case and lab data. Like a neighborhood watch for mosquito-borne disease, this surveillance gives early warning about outbreaks and trends, information that matters to investors because it can affect health-care demand, vaccine and diagnostic makers, travel and tourism, insurers, and regional economic activity.

pcr technical

"Vector Smart provides mosquito abatement districts with rapid, local PCR data"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

assay medical

"independent evaluation of the Company's Vector Smart VZDC assay"

An assay is a laboratory test that detects or measures how much of a specific substance is present or how well something performs, like measuring a drug’s concentration, a material’s purity, or a biomarker’s level. For investors, assay results act like a thermometer or quality check: they provide objective evidence about a product’s effectiveness, safety, or manufacturing consistency, and can strongly influence regulatory approval, market acceptance, and company valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana

State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of two new Vector Smart® mosquito surveillance laboratory installations in Florida, with installation and customer training underway at an additional laboratory in Indiana. The installations bring previously announced orders into operation and expand a Vector Smart network that has served customers across 21 U.S. states, including 7 mosquito abatement districts in Florida.

Dengue activity in Florida has increased significantly this season. According to the Florida Department of Health's arbovirus surveillance report for the week ending August 29, 2026, the state has recorded 73 locally acquired dengue cases across five counties and identified 14 dengue-positive mosquito pools. These conditions highlight the pressing need for decentralized molecular surveillance. Vector Smart provides mosquito abatement districts with rapid, local PCR data that supports more informed public health decision-making while strengthening the Company's growing installed surveillance network.

"Every new Vector Smart deployment expands more than our customer footprint. It extends a growing molecular monitoring network that enables public health agencies to generate faster, local insights into mosquito-borne disease activity," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "As vector-borne diseases continue to emerge in new regions, we believe decentralized PCR surveillance will become an increasingly important component of public health infrastructure. Bringing additional laboratories online is another step toward building that network."

Mr. Egan continued, "We designed Vector Smart as a scalable, multi-test surveillance platform rather than a single-test solution. Once a laboratory is operational, customers can leverage the same workflow across multiple mosquito-borne pathogens as surveillance priorities evolve. We believe that flexibility strengthens the long-term value of the platform while supporting continued growth in recurring assay demand as our installed base expands."

The Florida and Indiana laboratory deployments represent the latest phase of the Vector Smart expansion program announced on June 25, 2026, as previously disclosed customer orders become operational. The installations follow the Company's recently announced first international Vector Smart deployment and ongoing third-party validation of the platform. Most recently, an additional state public health laboratory completed an independent evaluation of the Company's Vector Smart VZDC assay, building on prior independent evaluations supporting broader adoption across mosquito surveillance and public health programs.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's ability to expand deployment and adoption of its Vector Smart® platform, the expected demand for mosquito surveillance and public health monitoring solutions, the Company's ability to commercialize the Vector Smart platform and related products, the anticipated benefits of recent customer deployments, the significance of independent third-party evaluations of the Company's assays, the potential for recurring consumable demand as the Vector Smart installed base grows, the Company's plans to expand the Vector Smart platform into additional domestic and international markets, and the expected performance and market acceptance of the Vector Smart platform and related assays. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks related to the Company's ability to successfully commercialize the Vector Smart platform and related products; risks related to the Company's ability to commercialize the Vector Smart platform and related products in strategically important markets, including risks that customers, distributors, and public health agencies may not successfully adopt, deploy, or utilize the Company's products; risks associated with international operations, including changing regulatory requirements, economic conditions, reimbursement environments, import/export restrictions, and foreign currency fluctuations; risks related to regulatory review by regulatory authorities that would be required to achieve a successful commercial launch; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform and other Co-Dx technology; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-completes-new-vector-smart-laboratory-installations-amid-rising-dengue-activity-in-florida-302874606.html

SOURCE Co-Diagnostics

FAQ

What recent dengue activity in Florida provides context for these Vector Smart installations?

For the season through the week ending August 29, 2026, Florida has recorded 73 locally acquired dengue cases across five counties and identified 14 dengue-positive mosquito pools, based on the state’s arbovirus surveillance report. The company said these conditions highlight the need for decentralized molecular surveillance.

How is the Vector Smart platform designed to be used over time?

Vector Smart is designed as a scalable, multi-test surveillance platform rather than a single-test solution. Once a laboratory is operational, customers can use the same workflow to monitor multiple mosquito-borne pathogens as surveillance priorities evolve. The company believes this flexibility supports long-term platform value and growth in recurring assay demand as the installed base expands.

How do these deployments relate to Co-Diagnostics’ broader Vector Smart expansion program?

The Florida and Indiana laboratory deployments are described as the latest phase of the Vector Smart expansion program announced on June 25, 2026, as previously disclosed customer orders become operational. They follow the company’s recently announced first international Vector Smart deployment and ongoing third-party validation of the platform.